Vertex Pharmaceuticals Incorporated Return on Equity

Vertex Pharmaceuticals Incorporated posts a ROE of 21.76%. That is above the Healthcare sector average of -100.59%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near -100.59% is typical. Vertex Pharmaceuticals Incorporated's 21.76% is higher that level. That is roughly 121.6% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Vertex Pharmaceuticals Incorporated's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 21.76%; use YoY and peer views to separate noise from signal.

Context for VX1.DE's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -100.59%), and (3) consistency with growth and profitability. This page covers the first two; Vertex Pharmaceuticals Incorporated's other metric pages and overview cover the third.

Judging Vertex Pharmaceuticals Incorporated against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 21.76% here, then scan peer and history charts to see if the gap is persistent.